22:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing...
04:19 , Jan 4, 2019 |  BC Week In Review  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic in 2019, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Dec. 28 to raise $100 million in an IPO on NASDAQ. TCR2...
22:56 , Dec 28, 2018 |  BC Extra  |  Financial News

TCR2 seeks IPO as first program slated to enter clinic

Looking to bring at least one of its cell therapy programs to the clinic next year, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Friday to raise $100 million in an IPO on NASDAQ. TCR2 is...
23:06 , Dec 27, 2018 |  BC Extra  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed Thursday to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing tri-specific T...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
15:57 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million on Nov. 11 in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of...
21:02 , Nov 12, 2018 |  BC Extra  |  Financial News

Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of its T cell...
21:52 , Oct 5, 2018 |  BC Extra  |  Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in...
20:33 , Oct 5, 2018 |  BC Week In Review  |  Company News

Janssen terminates licenses to Aduro cancer therapies

Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told...
15:36 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sobi grabs Emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million)...